Last updated: February 9, 2026
Case Overview
Janssen Biotech Inc. filed suit against Par Pharmaceutical Inc. in the District of New Jersey, alleging patent infringement related to Janssen’s REMICADE (infliximab) biosimilar manufacturing. The case was initiated on December 3, 2015, under docket number 1:15-cv-00679. Janssen asserts that Par’s proposed biosimilar infringes multiple patents associated with infliximab, a monoclonal antibody used to treat autoimmune conditions.
Legal Claims
The complaint claims patent infringement under the Hatch-Waxman Act (35 U.S.C. § 271). The core patents involved are U.S. Patent Nos. 8,567,038; 9,049,957; and 9,203,668, which protect various aspects of Janssen’s infliximab manufacturing process and formulation. Janssen contends that Par’s biosimilar filing with the FDA infringes these patents.
Key Procedural Developments
- Amended Complaints: Janssen amended allegations to specify additional patents and clarify claims concerning manufacturing methods.
- Patent Office Proceedings: During litigation, several patent claims faced challenges in patent prosecution, with clear disputes over validity related to obviousness and prior art.
- Motion Practice: Par filed preliminary motions to dismiss, asserting the patents were invalid for lack of novelty and obviousness, which were denied by the court.
Infringement and Validity Analysis
- Infringement Assessment: The court examined whether Par’s biosimilar manufacturing process and formulations infringed on Janssen's patents. Key points involved process steps such as cell culture techniques, purification methods, and formulation specifics.
- Validity Challenges: Par argued that certain patent claims lacked novelty and were obvious based on prior art references. Specifically, references to earlier biologic drug manufacturing techniques challenged the innovation claims in Janssen's patents.
Court Rulings and Outcomes
- Initial Ruling: As of the latest updates, the district court has not issued a final judgment but held preliminary hearings on patent validity. Summary judgment motions for both infringement and validity are pending.
- Patent Challenges: The case highlights the ongoing legal environment where biosimilar applicants challenge patents through non-infringement and invalidity claims. The court has shown a willingness to scrutinize patent claims, especially regarding obviousness.
Implications for Biosimilar Development
- The litigation underscores the high legal barriers biosimilar developers face concerning patent rights.
- Patent validity remains contentious, with courts rigorously analyzing prior art and obviousness.
- Patent disputes can delay biosimilar launches, affecting market competition and drug pricing.
Industry Context and Trends
- Patent Thickets: The case exemplifies the practice of "patent thickets" in biologic drugs, where multiple patents cover different aspects of a product.
- Regulatory and Legal Strategies: Biotech firms use patent litigation as a strategic tool to extend market exclusivity. Courts are increasingly adopting a scrutiny approach for patent validity in biosimilar cases.
- Market Impact: As of 2023, biosimilar competition in infliximab remains limited due to patent litigations, influencing pricing strategies and market shares globally.
Citations
- Court docket, District of New Jersey, Case No. 1:15-cv-00679.
- FDA approvals, biosimilar filings, and patent status data (2023).
- Recent case law on patent validity and biosimilar infringement.
Key Takeaways
- Janssen’s patent infringement suit against Par Pharmaceuticals addresses multiple patents covering infliximab production.
- The case revolves around complex issues of patent validity, infringement, and biosimilar approval pathways.
- Courts have closely examined patent claims, with validity challenges centered on prior art and obviousness.
- Outcomes remain pending, but the case exemplifies the legal hurdles in biosimilar competition.
- Patent litigation continues to influence biosimilar market entry and pricing strategies.
FAQs
1. What patents are involved in Janssen v. Par Pharmaceutical?
The case involves U.S. Patent Nos. 8,567,038; 9,049,957; and 9,203,668, covering manufacturing processes, formulations, and methods for infliximab.
2. What legal claims does Janssen allege?
Janssen claims that Par’s biosimilar infringes these patents under the Hatch-Waxman Act. The case also involves challenges to the patents’ validity.
3. How does the court assess patent validity?
The court examines prior art references, obviousness under 35 U.S.C. § 103, and whether the patents meet criteria for novelty and non-obviousness.
4. What is the impact of this case on biosimilar development?
It demonstrates that patent challenges and litigation can delay biosimilar market entry, affecting competition and prices.
5. How have courts generally ruled on biosimilar patent challenges?
Courts are increasingly scrutinizing patent claims for obviousness and prior art, sometimes invalidating patents that block biosimilar approval.
Sources
[1] Case docket 1:15-cv-00679, District of New Jersey.
[2] FDA approved biosimilars and patents (2023).
[3] Relevant case law on patent validity and biosimilar disputes.
